Chimiro cheEurope che3'-Hydroxy-3-Biphenylcarboxylic Acid Citric Acid 77-92-9

Quality First, uye Client Supreme ndiyo nhungamiro yedu yekupa rubatsiro rwakanyanya kune vatengesi vedu. Mazuva ano, tanga tichiedza zvakanyanya kuti tive pakati pevanotengesa zvinhu kunze kwenyika mukati memunda wedu kuti tizadzise vatengi vanozoda kuEurope style ye3′- Hydroxy-3-Biphenylcarboxylic Acid Citric Acid 77-92-9, Kuburikidza neanopfuura makore masere ebhizinesi diki, isu taunganidza ruzivo rwakapfuma uye matekinoroji epamberi panguva yekugadzira zvigadzirwa zvedu.
Quality First, uye Client Supreme ndiyo nhungamiro yedu yekupa rubatsiro rwepamusoro kune vatengi vedu. Mazuva ano, tanga tichiedza nepatinogona napo kuti tive pakati pevanotengesa zvinhu kunze kwenyika mukati memunda wedu kuzadzisa vatengi vanozodaChina 77-92-9 uye CAS 77-92-9, Kubva pane yedu otomatiki yekugadzira mutsara, yakatsiga yekutenga zvinhu chiteshi uye nekukurumidza subcontract masisitimu akavakwa mu mainland China kuti asangane nehupamhi uye hwepamusoro zvinodiwa mumakore achangopfuura.Tanga tichitarisira kushanda pamwe nevatengi vakawanda pasi rese kuti tive nebudiriro yakafanana!Kuramba takatendeseka, hunyanzvi uye hunoshanda, isu tinotarisira nemoyo wese kuti isu tinogona kuve vashandi vebhizinesi kugadzira ramangwana redu rakajeka!

2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid inoshandiswa sepakati peEltrombopag.
Eltrombopag, yakagadziridzwa naGlaxoSmithKline (GSK) kuUK uye yakazogadziriswa pamwe chete neNovartis kuSwitzerland, ndiyo yekutanga uye yakatenderwa chete mamorekuru madiki asiri peptide TPO receptor agonist munyika.Eltrombopag yakabvumidzwa neUS FDA muna 2008 kurapwa kweidiopathic thrombocytopenic purpura (ITP), uye muna 2014 kurapwa kweaplastic anemia (AA).Ndiwo zvakare mushonga wekutanga wakabvumidzwa neUS FDA kurapwa kweAA mumakore makumi matatu apfuura.
Muna Zvita 2012, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvarwere vane chisingaperi hepatitis C (CHC), kuitira kuti varwere veHepatitis C vane hurombo husina kunaka nekuda kwekuderera kweplatelet count vanogona kutanga nekuchengetedza interferon based standard therapy yezvirwere zvechiropa.Musi waFebruary 3, 2014, GlaxoSmithKline yakazivisa kuti FDA yakapa mukana wekurapa mushonga weEltrombopag kurapwa kwehemopenia muvarwere vane yakanyanya chemicalbook aplastic anemia (SAA) vasina kupindura zvizere kune immunotherapy.Musi waNyamavhuvhu 24, 2015, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvakuru nevana vane makore 1 uye kupfuura vane chronic immune thrombocytopenia (ITP) vasina mhinduro yakakwana kune corticosteroids, immunoglobulins kana splenectomy.Musi waJanuary4, 2018, Eltrombopag yakabvumidzwa kunyorwa muChina kurapwa kwekutanga immune thrombocytopenia (ITP).

Quality First, uye Client Supreme ndiyo nhungamiro yedu yekupa rubatsiro rwakanyanya kune vatengesi vedu. Mazuva ano, tanga tichiedza zvakanyanya kuti tive pakati pevanotengesa zvinhu kunze kwenyika mukati memunda wedu kuti tizadzise vatengi vanozoda kuEurope style ye3′- Hydroxy-3-Biphenylcarboxylic Acid Citric Acid 77-92-9, Kuburikidza neanopfuura makore masere ebhizinesi diki, isu taunganidza ruzivo rwakapfuma uye matekinoroji epamberi panguva yekugadzira zvigadzirwa zvedu.
Europe maitiro eChina 77-92-9 uye CAS 77-92-9, Kubva pane yedu otomatiki yekugadzira mutsara, yakatsiga yekutenga zvinhu chiteshi uye nekukurumidza subcontract masisitimu akavakwa mu mainland China kuti asangane nehupamhi uye hwepamusoro zvinodiwa mumakore achangopfuura.Tanga tichitarisira kushanda pamwe nevatengi vakawanda pasi rese kuti tive nebudiriro yakafanana!Kuramba takatendeseka, hunyanzvi uye hunoshanda, isu tinotarisira nemoyo wese kuti isu tinogona kuve vashandi vebhizinesi kugadzira ramangwana redu rakajeka!